摘要
目的探讨MORA生物物理治疗仪联合布地奈德福莫特罗治疗过敏性支气管哮喘的临床疗效及其安全性。方法选择2016年6月至2017年12月60例符合纳入标准的支气管哮喘患者,将其随机分为对照组与试验组,每组30例。对照组施以布地奈德福莫特罗吸入及常规治疗,试验组在对照组的治疗基础上加用MORA生物物理治疗仪治疗。分别于治疗后3、6个月观察对比两组患者日间/夜间症状评分、哮喘生命质量问卷、肺功能指标以及临床疗效,并观察记录不良反应的发生情况。结果治疗前,两组患者日间症状评分、夜间症状评分、哮喘生命质量问卷及肺功能指标(FEV1、FEV1%、PEF)的比较差异均无统计学意义(P>0. 05);两组患者治疗前后组内比较,上述各项观察指标均有明显改善,差异有统计学意义(P<0. 05);两组患者治疗后3、6个月分别进行组间比较,试验组上述指标优于对照组,差异有统计学意义(P<0. 05)。治疗后两组患者临床疗效比较,试验组优于对照组(43.33% vs 66.67%,P<0. 05)。对照组发生震颤3例,胃肠道症状4例,不良反应发生率为23.33%;试验组发生震颤2例,胃肠道症状4例,不良反应发生率为20. 00%;两组不良反应发生率比较差异无统计学意义(P>0. 05)。结论 MORA生物物理治疗仪联合布地奈德福莫特罗吸入治疗过敏性支气管哮喘的疗效显著,能够更有效的改善患者的肺功能及临床症状,且不会增加不良反应发生率。
Objective To explore the clinical efficacy and safety of MORA bioresonance therapy combined with budesonide/formoterol in the treatment of allergic bronchial asthma. Methods Sixty patients with bronchial asthma meeting the inclusion criteria from June 2016 to December 2017 were randomly divided into control group and experimental group（ n = 30,each）. The budesonide/formoterol plus conventional treatment was given in control group,and MORA bioresonance therapy was added in experimental group based on the treatment regimen of control group. At 3 and 6 months after treatment,daytime/night symptom score,asthma quality of life questionnaire,pulmonary function index,clinical efficacy and adverse reactions were observed and compared between two groups. Results Before treatment,there were no significant differences in daytime/night symptom score,asthma quality of life questionnaire and pulmonary function index（ FEV1,FEV1%,PEF） between two groups（ all P>0. 05）. Compared with before treatment,the above-mentioned indexes were significantly improved after treatment in both two groups（ all P < 0. 05）. After 3-and 6-month of treatment,all observation indexes in experimental group significantly improved compared with those in control group（ P < 0. 05）. The curative effect in experimental group was statistically better than that in control group（ 93. 33% vs 66. 67%,P<0. 05）. In control group,there were 3 cases with tremor,and 4 cases with gastrointestinal symptoms. In experimental group,tremor occurred in 2 cases,gastrointestinal symptoms occurred in 4 cases. There was no significant difference in the incidence of adverse reactions between experimental group and control group（ 23. 33% vs 20. 00%,P > 0. 05）. Conclusion MORA bioresonance therapy combined with budesonide/formoterol has obvious effect in the treatment of allergic bronchial asthma and can improve patient’s lung function and clinical symptoms more effectively without increasing the incidence of adverse reactions.
作者
邓嘉宁
农正道
DENG Jia-ning;NONG Zheng-dao(Department of Respiratory Medicine,the Third Affiliated Hospital of Guangxi Medical University,Nanning,Guan'gxi 530031,China)
出处
《中国临床研究》
CAS
2018年第12期1640-1643,共4页
Chinese Journal of Clinical Research
基金
广西壮族自治区卫生和计划生育委员会科研课题(Z2016229)
